Arrowhead Pharmaceuticals Inc.
- BID
64.92
- ASK
65.12
- 308 Units307 Units
- 07/21, 17:04:25 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
287.38%
Market Cap
2.93 Bil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.01 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 64.92 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 05:04:25 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 64.92 | 62.42 |
| PREV. DAY'S PRICE | 62.6 | (07/20) |
| CHANGE DAY BEFORE | +2.32 | 3.71 % |
| 52 WEEK HIGH / LOW | 76.38 (07/07) | 12.49 (07/22) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.80 | -4.62 | -0.01 | -2.74 | -3.63 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 10.63 | 12.99 | 10.04 | - | - |
PRICE - SALES RATIO | 11.92 | 653.40 | 5.56 | - | - |
PRICE - CASH FLOW RATIO | - | - | 25.69 | - | - |
Master Data
| WKN | A2AGYB |
| ISIN | US04280A1007 |
| SYMBOL | HDP1 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Arrowhead Research |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 123.90 Mil. |
| MARKET CAPITALISATION | 2.93 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -10.84 % | -11.36 % | 9.71 % | 12.67 % | 287.38 % | 108.76 % | 21.20 % | 10.84 % |
| HIGH | 66.70 | 76.38 | 76.38 | 76.38 | 76.38 | 76.38 | 76.38 | 76.38 |
| LOW | 61.12 | 61.12 | 57.58 | 47.18 | 12.49 | 8.60 | 8.60 | 47.18 |
Dividende
pro Aktie
Arrowhead Research does not deliver dividend information
Company profile
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Structured products for Arrowhead Pharmaceuticals Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.